Evaluation of myocardial fibrosis and wall motion abnormality with ⁶⁸Ga-FAPI PET/MR in coronary heart disease.

ABSTRACT:

Background

To explore the characteristics of cardiac fibroblast activation protein inhibitor (FAPI) PET/MR in coronary heart disease (CHD) and its association with abnormal wall motion.

Results

In this prospective study, participants with CHD after PCI (Percutaneous Coronary Intervention) underwent gallium 68 (⁶⁸ Ga)-labeled FAPI PET/MR imaging. FAP signal was quantified using standardized uptake values. Cardiac MRI yielded functional parameters and area of injury (MRI non-viable). Abnormal wall motion identified by myocardial strain analysis was evaluated using integrated analysis of late gadolinium enhancement (LGE) and FAP signal. The correlations between FAP signal and clinical parameters were explored. Forty-two participants were included and FAP signal was h

SUBMITTER: Luo R 

PROVIDER: S-EPMC12279661 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature